Reimbursement: economics of orphan drugs and the impact of rarity on the estimation of cost effectiveness ration

Increasing pressures on health care budgets have led to a growing interest in the use of economic evaluation in reimbursement decisions for drugs and other health technologies. This has a great impact in the access of orphan drugs by rare disease patients. In this scenario, insurance companies are starting to assess the value for money by comparing the incremental costs …

Download Ebook: Top AMNOG resolutions for 2013

  AMNOG:  In January 2011, following pressure to reduce annual spending on the German healthcare budget, price controls were introduced in Germany through the AMNOG based pricing system. There is considerable anxiety within the industry as to whether a feasible price will be received in Germany and given the uncertainties, whether effective launch planning is possible. Here we summarise the …